Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating

Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price target at $50.00.

Yanan Zhu has given his Buy rating due to a combination of factors related to Intellia Therapeutics’ recent developments and expert opinions. The primary reason is the expert’s assessment that the Grade 4 liver enzyme adverse events reported in Intellia’s trials are not of significant concern. The expert highlighted that the liver can compensate for the damage indicated by ALT/AST levels, and since there is no abnormality in liver function, the events are considered idiosyncratic and not alarming given their low occurrence rate.
Furthermore, the expert mentioned that the elevated bilirubin levels, which were below the concerning threshold, do not pose a significant risk. The expert also noted that the potential causes of these events could be speculative and related to specific treatment mechanisms. Overall, the expert’s perspective, combined with the serious nature of the disease Intellia is targeting and the potential benefits of their treatment, supports the Buy rating.

According to TipRanks, Zhu is an analyst with an average return of -5.3% and a 30.74% success rate. Zhu covers the Healthcare sector, focusing on stocks such as uniQure, Regulus, and Ionis Pharmaceuticals.

In another report released on June 5, Bernstein also maintained a Buy rating on the stock with a $14.00 price target.